

TECHNICAL MANUAL

CD28 Blockade Bioassay

Instructions for Use of Products
JA6101 and JA6105

CD28 Blockade Bioassay

All technical literature is available at: www.promega.com/protocols/
 Visit the website to verify that you are using the most current version of this Technical Manual.
 Email Promega Technical Services if you have questions on use of this system: techserv@promega.com

1. Description	2
2. Product Components and Storage Conditions	7
3. Before You Begin	8
3.A. Materials to Be Supplied by the User	8
4. Assay Protocol	9
4.A. Preparing Assay Buffer, Antibody Samples and Bio-Glo™ Reagent	9
4.B. Plate Layout Design	11
4.C. Preparing Antibody Serial Dilutions	12
4.D. Preparing aAPC/Raji Cells	13
4.E. Preparing CD28 Effector Cells	14
4.F. Adding CD28 Effector Cells, Antibody and aAPC/Raji Cells to Assay Plates	14
4.G. Adding Bio-Glo™ Reagent	14
4.H. Data Analysis	15
5. Troubleshooting	15
6. References	16
7. Appendix	17
7.A. Representative Assay Results	17
8. Summary of Changes	18

1. Description

The human immune system is regulated by a complex network of inhibitory and stimulatory receptors that facilitate the elimination of pathogens, while maintaining tolerance to self-antigens. T cells play a central role in cell-mediated immunity against pathogens; however, T cells also contribute to the pathogenesis and exacerbation of autoimmune disorders.

Optimal activation of naive T cells is initiated by engagement of the T cell antigen receptor (TCR)/CD3 complex and the costimulatory receptor CD28. CD28 binds to the B7 family members CD80 and CD86 (collectively referred to as B7 in this technical manual) on antigen-presenting cells (APCs). Costimulation of T cells by CD28 activation initiates signaling cascades that result in AP-1 and NFκB transcription factor activation and nuclear translocation (1). These pathways significantly enhance T cell cytokine production—specifically, interleukin (IL)-2—which promotes T cell proliferation, differentiation and survival (2).

Blockade of CD28 has proven beneficial in preclinical and clinical studies to reduce autoimmunity and alloimmunity (3,4). Specifically, the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)-Fc fusion proteins, abatacept and belatacept are FDA-approved for the treatment of rheumatoid arthritis and renal transplantation, respectively. CTLA-4-Fc proteins work by binding B7 on APCs, thereby inhibiting CD28 activation of T cells. However, these proteins similarly block intrinsic inhibitory signaling functions of CTLA-4, which may inadvertently boost effector responses in some settings. Therefore, specifically targeting CD28 may be more beneficial than targeting B7, especially in the setting of allograft rejection (5,6,7).

Activation of CD28 by agonist antibodies is a separate immunotherapy strategy to re-activate the immune system in settings of chronic infection or cancer. The CD28 Blockade Bioassay is not designed to detect agonistic activity of CD28 antibodies. The CD28 Bioassay (Cat.# JA6701) for screening and potency testing of CD28 agonist antibodies is available separately.

There are no easy-to-use functional bioassays available to measure the in vitro potency of potential biologic drugs that block the interaction between CD28/B7. Quantitative bioassays are needed in the development of biologic drugs designed to block CD28. Current methods rely on primary human T cells and APCs, and measurement of functional endpoints such as cell proliferation, cell surface marker expression and cytokine production. These assays are laborious and highly variable due to their reliance on donor cells, complex assay protocols and unqualified assay reagents. As a result, these assays are difficult to establish in a potential quality-controlled drug development setting.

The CD28 Blockade Bioassay^(a-e) (Cat.# JA6101, JA6105) is a bioluminescent reporter cell-based assay that overcomes the limitations of existing assays. It can be used to measure the potency and stability of antibodies and other potential biologics that block CD28/B7 (8). The assay consists of two genetically engineered cell lines:

- **CD28 Effector Cells:** Jurkat T cells expressing endogenous TCR/CD3 and CD28, and a luciferase reporter driven by TCR/CD3 and CD28 pathway-dependent response elements
- **aAPC/Raji Cells:** Raji cells expressing an engineered cell surface protein designed to activate TCR/CD3 in an antigen-independent manner, and endogenously expressing the B7 ligands

The CD28 Effector Cells and aAPC/Raji Cells are provided in thaw-and-use format as cryopreserved cells that can be thawed, plated and used in an assay without the need for cell culture and propagation.

When the two cell types are cocultured, the aAPC/Raji Cells activate TCR/CD3 and CD28 on the Effector Cells to induce maximum promoter-mediated luminescence. Addition of a biologic that blocks CD28/B7 inhibits costimulation by CD28 and results in decreased promoter-mediated luminescence (Figure 1). The bioluminescent signal is quantified using the Bio-Glo™ Luciferase Assay System, and a standard luminometer such as the GloMax® Discover System.

In addition to the CD28 Blockade Bioassay, we offer Control Ab, Anti-CD28 (Cat.# K1231), for use as a positive control.

The CD28 Blockade Bioassay combines a simple, add-mix-read one-day workflow with CD28 Effector Cells and aAPC/Raji Cells provided in a frozen thaw-and-use format, with an optimized protocol. Together, they yield a quantitative bioassay that exhibits low variability and high accuracy. The thaw-and-use cells provided in the CD28 Blockade Bioassay kits are manufactured under stringent quality control to provide high assay reproducibility with the convenience of an assay reagent that eliminates the need for continuous cell propagation.




Figure 1. Representation of the CD28 Blockade Bioassay. The bioassay consists of two cell lines, CD28 Effector Cells and aAPC/Raji Cells. When cocultured, the aAPC/Raji Cells activate TCR/CD3 and CD28 on the Effector Cells to induce maximum promoter-mediated luminescence. Addition of a biologic that blocks CD28/B7 inhibits T cell costimulation by CD28 and results in decreased promoter-mediated luminescence, which can be detected in a dose-dependent manner by addition of Bio-Glo™ Reagent and quantitation with a luminometer.

1. Description (continued)

The CD28 Blockade Bioassay reflects the mechanism of action (MOA) of biologics designed to block CD28/B7 interactions. Specifically, CD28 activation-mediated luminescence is reduced following the addition of a CD28 blocking biologic but not following addition of anti-ICOS or anti-PD-1 blocking Abs (Figure 2). The bioassay is prequalified following International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines and shows the precision, accuracy and linearity required for routine use in potency and stability studies (Table 1 and Figure 3). The bioassay can be performed in a one-day timeframe, and the workflow is simple, robust and compatible with both 96- and 384-well plate formats used for antibody screening in early drug discovery (Figure 4). In addition, the bioassay can be used with up to 10% human serum (in antibody samples; Figure 5), indicating potential for further development into a neutralizing antibody bioassay.




Figure 2. The CD28 Blockade Bioassay reflects the mechanism of action (MOA) and specificity of biologics designed to block the CD28/B7 interaction. CD28 Effector Cells were incubated with aAPC/Raji Cells in the presence of serial titrations of blocking Abs as indicated. After a 5-hour induction, Bio-Glo™ Reagent was added and luminescence quantified using the GloMax® Discover System. Data were fitted to a four-parameter logistic curve using GraphPad Prism® software. Data were generated using thaw-and-use cells.

Table 1. The CD28 Bioassay Shows Precision, Accuracy and Linearity.

Parameter	Results	
Accuracy	% Expected Relative Potency	% Recovery
	50	54.2
	70	68.7
	100	103.1
	140	136.5
	200	202.8
Repeatability (% CV)	100% (Reference)	15.2
Intermediate Precision (% CV)		13.2
Linearity (r^2)		0.997
Linearity ($y = mx + b$)		$y = 0.993x - 1.802$
A 50–200% theoretical potency series of Control Ab, Anti-CD28, was analyzed in triplicate in three independent experiments performed on three days by two analysts. Bio-Glo™ Reagent was added, and luminescence was quantified using the GloMax® Discover System. Data were analyzed and relative potencies were calculated after parallelism determination using JMP® software. Data were generated using thaw-and-use cells.		




Figure 3. The CD28 Blockade Bioassay is stability-indicating. Samples of Control Ab, Anti-CD28, were maintained at 4°C (control) or heat-treated at the indicated times and temperatures, then analyzed using the CD28 Blockade Bioassay. Bio-Glo™ Reagent was added and luminescence quantified using the GloMax® Discover System. Data were fitted to a four-parameter logistic curve using GraphPad Prism® software. Data were generated using thaw-and-use cells.

1. Description (continued)




Figure 4. The CD28 Blockade Bioassay is amenable to 384-well plate format. **Panel A.** The CD28 Blockade Bioassay was performed in 96-well plates, as described in this technical manual, with a titration of Control Ab, Anti-CD28. **Panel B.** The CD28 Blockade Bioassay was performed in 384-well format as briefly described here. A titration of 3X concentrated Control Ab, Anti-CD28 (Cat. # K1231), was serially diluted and added to a 384-well white assay plate at 5 μ l/well. CD28 Effector Cells were added to the plate at 2×10^4 cells/5 μ l/well. The aAPC/Raji Cells at 2×10^4 cells/5 μ l/well were then added to the plate. After 5-hour assay incubation at 37°C, 5% CO₂, 15 μ l of Bio-Glo™ Reagent was added and luminescence quantified using the GloMax® Discover System. Data were fitted to a four-parameter logistic curve using GraphPad Prism® software. The IC₅₀ values were 16ng/ml for both formats and the percent inhibition was 51% and 50% for 96- and 384-well format, respectively. Data were generated using thaw-and-use cells.




Figure 5. The CD28 Blockade Bioassay is tolerant to human serum. Control Ab, Anti-CD28, was analyzed in the absence or presence of pooled normal human serum (0% or 10% in the antibody sample). Bio-Glo™ Reagent was added and luminescence quantified using the GloMax® Discover System. Data were fitted to a four-parameter logistic curve using GraphPad Prism® software. The CD28 Blockade Bioassay was tolerant to $\leq 10\%$ human serum from two different serum pools (data shown for one). Higher concentrations of human serum may alter the bioassay performance. Data were generated using thaw-and-use cells.

2. Product Components and Storage Conditions

PRODUCT	SIZE	CAT.#
CD28 Blockade Bioassay	1 each	JA6101

Not for Medical Diagnostic Use. Each kit contains sufficient reagents for 120 assays using the inner 60 wells of two 96-well plates. Includes:

- 1 vial TCR/CD3 Effector Cells (IL-2), (CD28 Effector Cells, 0.8ml)
- 1 vial aAPC/Raji Cells (0.8ml)
- 36ml RPMI 1640 Medium
- 4ml Fetal Bovine Serum
- 1 vial Bio-Glo™ Luciferase Assay Substrate (lyophilized)
- 10ml Bio-Glo™ Luciferase Assay Buffer

PRODUCT	SIZE	CAT.#
CD28 Blockade Bioassay 5X	1 each	JA6105

Not for Medical Diagnostic Use. Each kit contains sufficient reagents for 600 assays using the inner 60 wells of ten 96-well plates. Includes:

- 5 vials TCR/CD3 Effector Cells (IL-2), (CD28 Effector Cells, 0.8ml)
- 5 vials aAPC/Raji Cells (0.8ml)
- 5 × 36ml RPMI 1640 Medium
- 5 × 4ml Fetal Bovine Serum
- 5 vials Bio-Glo™ Luciferase Assay Substrate (lyophilized)
- 5 × 10ml Bio-Glo™ Luciferase Assay Buffer

Notes:

- CD28 Effector Cells are labeled TCR/CD3 Effector Cells (IL-2). Please note the vial label when placing the vials into storage.
- The CD28 Blockade Bioassay components are shipped separately because of different temperature requirements. The CD28 Effector Cells and aAPC Raji Cells are shipped on dry ice. The Bio-Glo™ Luciferase Assay Substrate, Bio-Glo™ Luciferase Assay Buffer and Fetal Bovine Serum are shipped on dry ice, separately from the cells. The RPMI 1640 Medium is shipped at ambient temperature.

Storage Conditions:

- Upon arrival, immediately transfer the cell vials to below –140°C (freezer or liquid nitrogen vapor phase) for long-term storage. Do not store cell vials submerged in liquid nitrogen. **Do not** store cell vials at –80°C because this will negatively impact cell viability and cell performance.
- Store Bio-Glo™ Luciferase Assay Substrate, Bio-Glo™ Luciferase Assay Buffer and Fetal Bovine Serum at –30°C to –10°C. Avoid multiple freeze-thaw cycles of the serum.
- For optimal performance, use reconstituted Bio-Glo™ Reagent on the day of preparation. However, once reconstituted, Bio-Glo™ Reagent can be stored at –30°C to –10°C for up to 6 weeks.
- Store RPMI 1640 Medium at +2°C to +10°C protected from fluorescent light.

3. Before You Begin

Please read through the entire protocol to become familiar with the components and the assay procedure before beginning.

Note the catalog number and lot number from the cell vial box label. This information can be used to download documents for the specified product from the website, such as the Certificate of Analysis.

Note: The CD28 Bioassay uses the Bio-Glo™ Luciferase Assay System (Cat.# G7940, G7941) for detection.

The CD28 Blockade Bioassay is intended to be used with user-provided antibodies or other biologics designed to block the interaction of CD28/B7. Control Ab, Anti-CD28 (Cat.# K1231) is available separately for use in assay optimization and routine quality control. We strongly recommend including Control Ab, Anti-CD28, as a positive control in the first few assays to gain familiarity with the assay. Data generated using Control Ab, Anti-CD28, is shown in Section 7.A, Representative Assay Results.

The CD28 Effector Cells and aAPC Raji Cells are provided in frozen, thaw-and-use format and are ready to be used without any additional cell culture or propagation. When thawed and diluted as instructed, the cells will be at the appropriate concentration for the assay. The cells are sensitive and care should be taken to follow cell thawing and plating procedures as described. Do not overmix or overwarm the cell reagents.

The CD28 Blockade Bioassay produces a bioluminescent signal and requires a luminometer or sensitive luminescence plate reader. Bioassay development and performance data included in this Technical Manual were generated using the GloMax® Discover System. An integration time of 0.5 second/well was used for all readings. The bioassay is compatible with most other plate-reading luminometers, though relative light unit (RLU) readings will vary with the sensitivity and settings of each instrument. If using a reader with adjustable gain, we recommend a high gain setting. The use of different instruments and gain adjustment will affect the magnitude of the raw data, but should not affect the measured relative potency of test samples.

3.A. Materials to Be Supplied by the User

- user-defined anti-CD28/B7 antibodies or other biologics samples
- solid-white, flat-bottom 96-well assay plates (e.g., Corning® Cat.# 3917) or 384-well assay plates (e.g., Corning Cat.# 3570) for plating and reading luminescence
- sterile clear V-bottom 96-well plate with lid (e.g., Costar® Cat.# 3896) for preparing antibody dilutions
- pipettes (single-channel and 12-channel; for best results use both manual and electronic pipettes as needed)
- sterile 15ml and 50ml conical tubes
- sterile reagent reservoirs (e.g., Costar®/Corning® Cat.# 4870)
- 37°C, 5% CO₂ incubator
- 37°C water bath
- plate reader with glow luminescence measuring capability or luminometer (e.g., GloMax® Discover System or equivalent system)
- **optional:** Control Ab, Anti-CD28 (Cat.# K1231)

4. Assay Protocol

This assay protocol illustrates the use of the CD28 Blockade Bioassay to test two antibody samples against a reference sample in a single assay run. Each test and reference antibody is run in triplicate, in a 10-point dilution series, in a single 96-well assay plate using the inner 60 wells. Other experimental and plate layouts are possible but may require further optimization.

Note: When preparing test and reference antibodies, choose an appropriate starting concentration and dilution scheme to achieve a complete dose-response curve with proper upper and lower asymptotes and sufficient points on the slope. For reference, we use 13.3µg/ml as a starting concentration (1X) and 3.5-fold serial dilution when testing Control Ab, Anti-CD28.

4.A. Preparing Assay Buffer, Antibody Samples and Bio-Glo™ Reagent

1. **Assay Buffer:** On the day of the assay, prepare the assay buffer (90% RPMI 1640/10% FBS). Thaw the FBS overnight at 4°C or in a 37°C water bath on the day of use. Prepare 35ml of assay buffer in a 50ml conical tube by adding 3.5ml of FBS to 31.5ml of RPMI 1640 Medium. Mix well and warm to 37°C before use.

Note: The recommended assay buffer contains 10% FBS. This concentration of FBS works well for the Control Ab, Anti-CD28, that we tested. If you experience assay performance issues when using this assay buffer, we recommend testing different serum concentrations in the range of 0.5–10%.

2. **Test and Reference Samples:** Using assay buffer as the diluent, prepare starting dilutions (dilu1, 3X final concentration) of two test antibodies (140µl each) and one reference antibody (280µl) in 1.5ml tubes. Store the tubes containing antibody starting dilutions appropriately before making antibody serial dilutions.

Note: If you are using Control Ab, Anti-CD28 as a reference antibody in your assay, prepare a 280µl starting dilution with 40µg/ml of anti-CD28 antibody (dilu1, 3X final concentration) by adding 11.2µl of anti-CD28 stock (1.0mg/ml) to 268.8µl of assay buffer.

3. **Bio-Glo™ Reagent:** Thaw the Bio-Glo™ Luciferase Assay Buffer at 4°C overnight or in a room temperature water bath on the day of assay. Equilibrate the Bio-Glo™ Luciferase Assay Buffer to ambient temperature, protected from light. Transfer all of the Bio-Glo™ Luciferase Assay Buffer into the amber bottle containing the Bio-Glo™ Luciferase Assay Substrate and mix by inversion until the substrate is thoroughly dissolved. Equilibrate and store the reconstituted Bio-Glo™ Reagent at ambient temperature (22–25°C) protected from light before adding to assay plates. When stored appropriately, Bio-Glo™ Reagent will maintain at least 80% activity after 24 hours at ambient temperature. For reference, 10ml of Bio-Glo™ Reagent is sufficient to assay 120 wells in a 96-well format.



Note: The CD28 Blockade Bioassay is compatible only with Bio-Glo™ Luciferase Assay Reagent (Cat.# G7940, G7941). **Do not** use Bio-Glo-NL™ Luciferase Assay Reagent (Cat.# J3081, J3082) with the CD28 Blockade Bioassay.




Figure 6. Schematic protocol for the CD28 Blockade Bioassay.

4.B. Plate Layout Design

For the protocol described here, use the plate layout illustrated in Figure 7 as a guide. The protocol describes serial replicate dilutions ($n = 3$) of test and reference antibody to generate two ten-point dose-response curves for each plate.

Recommended Plate Layout Design													
	1	2	3	4	5	6	7	8	9	10	11	12	
A	B	B	B	B	B	B	B	B	B	B	B	B	Assay Buffer (B)
B	B	no Ab	dilu9	dilu8	dilu7	dilu6	dilu5	dilu4	dilu3	dilu2	dilu1	B	Reference Ab
C	B	no Ab	dilu9	dilu8	dilu7	dilu6	dilu5	dilu4	dilu3	dilu2	dilu1	B	Test Ab
D	B	no Ab	dilu9	dilu8	dilu7	dilu6	dilu5	dilu4	dilu3	dilu2	dilu1	B	Reference Ab
E	B	no Ab	dilu9	dilu8	dilu7	dilu6	dilu5	dilu4	dilu3	dilu2	dilu1	B	Test Ab
F	B	no Ab	dilu9	dilu8	dilu7	dilu6	dilu5	dilu4	dilu3	dilu2	dilu1	B	Reference Ab
G	B	no Ab	dilu9	dilu8	dilu7	dilu6	dilu5	dilu4	dilu3	dilu2	dilu1	B	Test Ab
H	B	B	B	B	B	B	B	B	B	B	B	B	Assay Buffer (B)

Figure 7. Example plate layout showing nonclustered sample locations of test antibody and reference antibody dilution series and wells containing assay buffer (denoted by “B”) alone.

4.C. Preparing Antibody Serial Dilutions

The instructions described here are for preparation of a single stock of 3.5-fold serial dilutions of a single antibody for analysis in triplicate (100µl of each dilution provides a sufficient volume for analysis in triplicate). Alternatively, you can prepare three independent stocks of serial dilutions to generate triplicate samples. To prepare 3.5-fold serial dilutions, you will need 280µl of reference antibody at 3X the highest antibody concentration in your dose-response curve. You will need 140µl of each test antibody at 3X the highest antibody concentration in each of the test antibody dose-response curves. For other dilution schemes, adjust the volumes accordingly.

Note: If you are using Control Ab, Anti-CD28, as a control in the assay, follow the instructions below to prepare a 3.5-fold serial dilution series.

1. On the day of the assay, prepare an appropriate amount of assay buffer as described in Section 4.A.
2. To a sterile clear V-bottom 96-well plate, add 140µl of reference antibody starting dilution (dilu1, 3X final concentration) to wells A11 and B11 (see Figure 8).
3. Add 140µl of test antibodies 1 and 2 starting dilution (dilu1, 3X final concentration) to wells E11 and G11, respectively (see Figure 8).
4. Add 100µl of assay buffer to other wells in these four rows, from column 10 to column 2.
5. Transfer 40µl of the antibody starting dilutions from column 11 into column 10. Mix well by pipetting. Avoid creating bubbles.
6. Repeat equivalent 3.5-fold serial dilutions across the columns from right to left through column 3. Do not dilute into column 2.

Note: Wells A2, B2, E2 and G2 contain 100µl of assay buffer without antibody as a negative control.

7. Cover the antibody dilution plate with a lid and keep at ambient temperature (22–25°C) while preparing aAPC/Raji Cells and CD28 Effector Cells.

Recommended Plate Layout for Antibody Dilutions Prepared from a Single Antibody Stock													
	1	2	3	4	5	6	7	8	9	10	11	12	
A		no Ab	dilu9	dilu8	dilu7	dilu6	dilu5	dilu4	dilu3	dilu2	dilu1		Reference Ab
B		no Ab	dilu9	dilu8	dilu7	dilu6	dilu5	dilu4	dilu3	dilu2	dilu1		Reference Ab
C													
D													
E		no Ab	dilu9	dilu8	dilu7	dilu6	dilu5	dilu4	dilu3	dilu2	dilu1		Test Ab 1
F													
G		no Ab	dilu9	dilu8	dilu7	dilu6	dilu5	dilu4	dilu3	dilu2	dilu1		Test Ab 2
H													

Figure 8. Example plate layout showing antibody serial dilutions.

4.D. Preparing aAPC/Raji Cells

Note: The thaw-and-use aAPC/Raji Cells included in this kit are sensitive and care should be taken to follow the cell thawing and plating procedures **exactly** as described. Do not overmix or overwarm the cell reagents. No additional cell culture or manipulation is required or recommended. We recommend that you thaw and dilute a maximum of two vials of thaw-and-use cells at any one time.

Follow institutional guidelines for handling, including use of personal protective equipment (PPE) and waste disposal for biohazardous material.

1. Label a sterile 15ml conical tube, "aAPC/Raji Cells". Add 3ml of prewarmed (37°C) assay buffer to a 15ml conical tube.
2. Remove one vial of aAPC/Raji Cells from storage at -140°C and transfer to the bench on dry ice. Thaw the cells in a 37°C water bath until just thawed (about 2 minutes). While thawing, gently agitate and visually inspect the vial. Do not invert.
3. Gently mix the cell suspension by pipetting, then transfer the cells (0.75ml) to the 15ml conical tube containing 3ml of assay buffer. Mix well by gently inverting the tube or pipetting 1–2 times.

4.E. Preparing CD28 Effector Cells

Note: The thaw-and-use CD28 Effector Cells included in this kit are sensitive and care should be taken to follow the cell thawing and plating procedures **exactly** as described. Do not overmix or overwarm the cell reagents. No additional cell culture or manipulation is required or recommended. We recommend that you thaw and dilute a maximum of two vials of thaw-and-use cells at any one time.

1. Label a sterile 15ml conical tube, "Effector Cells". Add 3ml of prewarmed (37°C) assay buffer to a 15ml conical tube.
2. Remove one vial of CD28 Effector Cells from storage at -140°C and transfer to the bench on dry ice. Thaw the cells in a 37°C water bath until just thawed (about 2 minutes). While thawing, gently agitate and visually inspect the vial.
3. Gently mix the cell suspension by pipetting, then transfer the cells (0.75ml) to the 15ml conical tube containing 3ml of assay buffer. Mix well by gently inverting the tube.

4.F. Adding CD28 Effector Cells, Antibody and aAPC/Raji Cells to Assay Plates

1. Mix the CD28 Effector Cells by tube inversion and transfer suspension to a sterile reagent reservoir. Using a multichannel pipette, immediately dispense 25µl of the cell suspension to each of the inner 60 wells of the assay plates.
2. Using a multichannel pipette, add 25µl of the appropriate antibody dilution (Figure 8) to the assay plates according to the plate layout in Figure 7. Gently swirl the assay plates to ensure mixing of the Effector Cells and antibody. We recommend preincubating the CD28 Effector Cells and antibody for 5 minutes at ambient temperature on the bench top prior to adding the aAPC/Raji Cells.
3. Mix the aAPC/Raji Cells by tube inversion and transfer the suspension to a sterile reagent reservoir. Using a multichannel pipette, immediately dispense 25µl of the cell suspension to each of the inner 60 wells of the assay plates. Gently swirl the assay plates to ensure mixing.
4. Dispense 75µl of assay buffer into the outermost wells, labeled "B" in Figure 7, to both assay plates.
5. Cover the assay plates with lids and incubate in a 37°C, 5% CO₂ incubator for 5 hours.

4.G. Adding Bio-Glo™ Reagent

Note: Bio-Glo™ Reagent should be at ambient temperature (22–25°C) when added to assay plates.

1. After the 5-hour incubation time, remove the assay plates from the incubator and equilibrate to ambient temperature for 15 minutes.
2. Using a manual multichannel pipette, add 75µl of Bio-Glo™ Reagent to the inner 60 wells of the assay plates, taking care not to create bubbles.
3. Add 75µl of Bio-Glo™ Reagent to wells B1, D1 and F1 of each assay plate to measure the background signal.
4. Incubate at ambient temperature for 5–10 minutes.

 **Note:** Varying the incubation time will affect the raw RLU values but should not significantly change the IC₅₀ value and percent inhibition.

5. Measure luminescence using a luminometer or luminescence plate reader.

4.H. Data Analysis

1. Determine the plate background by calculating the average RLU from wells B1, D1 and F1.
2. Calculate percent inhibition =
$$\frac{1 - \text{RLU (antibody - background)}}{\text{RLU (no antibody control - background)}} \times 100$$
3. Graph data as RLU versus Log_{10} [antibody] and percent inhibition versus Log_{10} [antibody]. Fit curves and determine the IC_{50} value of antibody response using appropriate curve-fitting software (such as GraphPad Prism® software).

5. Troubleshooting

For questions not addressed here, please contact your local Promega Branch Office or Distributor. Contact information available at: www.promega.com Email: techserv@promega.com

Symptoms	Causes and Comments
Low luminescence measurements (RLU readout)	Choose an instrument designed for plate-reading luminescence detection. Instruments designed primarily for fluorescence detection are not recommended. Luminometers measure and report luminescence as relative values, and actual RLU numbers will vary between instruments. Some models of luminometers with low sensitivity should be avoided. If using a reader with an adjustable gain, we recommend a high gain setting. Insufficient cells per well or low cell viability can lead to low RLU. Handle and plate cells according to the instructions to ensure a sufficient number of viable cells per well. Low activity of Bio-Glo™ Reagent leads to low RLU. Store and handle the Bio-Glo™ Reagent according to the instructions.
Weak assay response (low percent inhibition)	Optimize the concentration range of your test sample(s) to achieve a full dose response with complete upper and lower asymptotes. The IC_{50} value obtained in the CD28 Blockade Bioassay may vary from the IC_{50} value obtained using other methods, such as primary T cell-based assays. If untreated control RLU is less than 100X above plate reader background RLU, subtract plate reader background RLU from all samples prior to calculating percent inhibition.

6. References

1. Rudd, C.E., Taylor, A. and Schneider, H. (2009) CD28 and CTLA-4 coreceptor expression and signal transduction. *Immunol. Rev.* **229**, 12–26.
2. Thompson, C.B. *et al.* (1989) CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. *Proc. Natl. Acad. Sci. USA.* **86**, 1333–7.
3. Lubrano, E., Scryfall, S. and Perrotta, F.M. (2018) Abatacept for the treatment of psoriatic arthritis. *Expert Rev. Clin. Immunol.* **14**, 899–905.
4. Vincenti, F. *et al.* (2016) Belatacept and long-term outcomes in kidney transplantation. *N. Engl. J. Med.* **374**, 333–43.
5. Zhang, T. *et al.* (2011) Selective CD28 blockade attenuates acute and chronic rejection of murine cardiac allografts in a CTLA-4-dependent manner. *Am. J. Transplant.* **11**, 1599–609.
6. Watkins, B.K. *et al.* (2018) CD28 blockade controls T cell activation to prevent graft-versus-host disease in primates. *J. Clin. Invest.* **128**, 3991–4007.
7. Liu, D., Badell, I.R. and Ford, M.L. (2018) Selective CD28 blockade attenuates CTLA-4-dependent CD8+ memory T cell effector function and prolongs graft survival. *JCI Insight.* **3**, e96378.
8. Wang, J. *et al.* (2018) Cell-based reporter bioassays to evaluate the Fc gamma receptor-dependent agonistic activities for therapeutic antibodies targeting immune costimulatory receptors. *Cancer Res.* **78**, (13 Suppl.), Abstract no. 2732.

7. Appendix

7.A. Representative Assay Results

The following data were generated using the CD28 Blockade Bioassay using Control Ab, Anti-CD28 (Figure 9).




Figure 9. The CD28 Blockade Bioassay measures the blocking activity of Control Ab, Anti-CD28. CD28 Effector Cells, a titration of Control Ab, Anti-CD28 (Cat. # K1231), and aAPC/Raji Cells were added to a 96-well assay plate. After a 5-hour incubation at 37°C, Bio-Glo™ Reagent was added and luminescence measured using the GloMax® Discover System. Data were fitted to a four-parameter logistic curve using GraphPad Prism® software. The IC₅₀ was 49ng/ml and the percent inhibition was 65.4%.



8. Summary of Changes

The following changes were made to the 6/26 revision of this document:

1. Removed Section 7.B, Related Products.
2. Made minor text and formatting edits.

^(a)NOT FOR MEDICAL DIAGNOSTIC USE. FOR IN VITRO USE ONLY. BY USE OF THIS PRODUCT, RECIPIENT AGREES TO BE BOUND BY THE TERMS OF THIS LIMITED USE STATEMENT. If the recipient is not willing to accept the conditions of this limited use statement, and the product is unused, Promega will accept return of the unused product and provide the recipient with a full refund.

This product may not be further sold or transferred by the recipient and may be used only by the recipient, and then only for (1) research use, (2) discovery, development and monitoring of biologic drugs and vaccines, (3) quality assurance testing of biologic drugs and vaccines, and (4) product release assays for biologic drugs and vaccines. No other commercial use is allowed. "Commercial use" means any and all uses of this product by recipient for monetary or other consideration, including providing a service, information or data to unaffiliated third parties, and resale of this product for any use. Recipient has no right to propagate, modify, derivatize, genetically engineer or otherwise create variations of the cells or genes stably transfected within the cells. In addition, recipient must use Bio-Glo™ Luciferase Assay System purchased from Promega Corporation for all luminescence assays using this product or contact Promega to obtain a license for use of this product with reagents other than Promega's. PROMEGA MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING AS TO MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE WITH REGARDS TO THIS PRODUCT. The terms of this agreement shall be governed under the laws of the State of Wisconsin, USA.

^(b)U.S. Pat. No. 8,008,006.

^(c)Licensed from Lonza Cologne GmbH under U.S. Pat. Nos. 7,700,357, 8,192,990 and 8,003,389, European Pat. Nos. 1297119, 1522587, 1607484 and 1741778 and other pending and issued patents.

^(d)U.S. Pat. No. 10,077,244 and other patents.

^(e)Patent Pending.

© 2021–2026 Promega Corporation. All Rights Reserved.

GloMax and Lumit are registered trademarks of Promega Corporation. Bio-Glo and Bio-Glo-NL are trademarks of Promega Corporation.

Corning and Costar are registered trademarks of Corning, Inc. GraphPad Prism is a registered trademark of GraphPad Software, Inc. JMP is a registered trademark of SAS Institute, Inc.

Products may be covered by pending or issued patents or may have certain limitations. Please visit our website for more information.

All prices and specifications are subject to change without prior notice.

Product claims are subject to change. Please contact Promega Technical Services or access the Promega online catalog for the most up-to-date information on Promega products.